Trial Profile
Randomized Phase II Study to Investigate the Efficacy, Safety and Tolerability of ZK 230211 (25 mg vs. 100 mg) as Second-Line Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lonaprisan (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Bayer; Bayer HealthCare; Bayer HealthCare Pharmaceuticals
- 15 Jun 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 05 Apr 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 05 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.